ArticleBriefings in bioinformatics2025
Inferring cell-type-specific gene regulatory network from cellular transcriptomics data with GeneLink.
Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From descriptive to generative: foundation-model approaches for spatial transcriptomics.Briefings in bioinformatics · 2026Review
- IAGRN: An Interleaved-Attention Graph Neural Network for Gene Regulatory Network Inference.International journal of molecular sciences · 2026Article
- Inferring cell-specific gene regulatory networks based on causal graph embedding.Cell reports methods · 2026Article
- CaHoT-GRN: context-aware high-order topology learning for robust single-cell gene regulatory network inference.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Deciphering cell-type-specific gene regulatory networks (ctGRNs) is crucial for elucidating fundamental biological processes, such as tissue development and cancer progression. However, accurately inferring ctGRNs from high-dimensional transcriptomic data poses a significant challenge, primarily due to issues like data sparsity, cell heterogeneity, and over-smoothing (i.e. the tendency of node features to become indistinguishable after many graph convolution layers) in deep learning models. To tackle these obstacles, we present GeneLink+, an innovative framework for ctGRN inference leveraging directed graph link prediction (i.e. inferring causal regulator-target edges) tasks. Building upon the robust predictive capabilities of its primary version, GENELink, GeneLink+ incorporates residual-GATv2 blocks, which synergize dynamic attention mechanisms with residual connections. This architecture effectively mitigates information loss during the aggregation process and preserves cell-type-specific gene features, thereby enhancing the identification of regulatory mechanisms as well as the model's interpretability. Furthermore, GeneLink+ uses a modified dot product scheme with learnable weight parameters to adaptively prioritize informative gene pairs when scoring regulatory relationships, thus enabling more precise causal edge attribution. Comprehensive benchmarking across seven datasets demonstrated that GeneLink+ either outperforms or matches the performance of existing state-of-the-art methods in terms of predictive accuracy and biological relevance. Additionally, applications to a wide array of transcriptomic data, encompassing single-cell ribonucleic acid sequencing, small nuclear ribonucleic acid sequencing, and spatially resolved transcriptomics, have unveiled pivotal causal regulatory relationships in blood immune cells, Alzheimer's disease, and breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.